Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sanofi Q1 2015 Results – Interview With CFO Jérôme Contamine

PARIS, April 30, 2015 /PRNewswire/ — Watch video interview and read transcript: Topics covered in the interview include:  – Q1 2015 results – Guidance for 2015 – Recent launches – Diabetes – Genzyme – Animal Health and Consumer Healthcare – Vaccines – R&D pipeline – Emerging Markets About Sanofi  Sanofi, a global healthcare leader, discovers, […]

Read More »

Perrigo Rejects Latest Mylan Unsolicited Offer

DUBLIN, April 29, 2015 /PRNewswire/ — Perrigo Company plc (“Perrigo”) (NYSE: PRGO; TASE) today announced its rejection of the revised unsolicited offer from Mylan NV (“Mylan”) (NASDAQ: MYL) to acquire all of the outstanding shares of Perrigo for $75.00 per share in cash and 2.3 Mylan ordinary shares for each ordinary Perrigo share (the “Offer”). The […]

Read More »

Celgene (CELG) Dealmaking Continues With Two Pacts Worth $110 Million With Northern Biologics, Agios (AGIO)

CAMBRDIGE, Mass. – Celgene Corporation (CELG) has struck two deals with other pharmaceutical companies with a combined value of $110 million to advance its oncology platform, continuing the cancer drugmaking company’s deal making trend to advance its oncology pipeline. Today Celgene announced it entered into an $80 million agreement with Agios Pharmaceuticals (AGIO) to develop […]

Read More »

Mylan (MYL) Ups Bid for Perrigo (PRGO) to $32.7B, As M&A Hungry Hippos Continues

Pittsburgh, Penn.-based Mylan Pharmaceuticals, Inc. (MYL)’s has upped its previous $30 billion unsolicited bid for generic drugmaker Perrigo Company (PRGO) to $32.7 billion, a move Mylan said its advisors Goldman Sachs says is well in line with the “sufficient resources” the company has to tender such an offer. The new bid breaks down to $232.23 […]

Read More »

Heart Disease and Stroke Cost America Nearly $1 Billion a Day in Medical Costs, Lost Productivity

New Business Pulse Focuses on CDC’s Efforts to Protect American Workers’ Heart Health ATLANTA, GA–(Marketwired – April 29, 2015) – Nearly 800,000 Americans die each year from heart disease, stroke and other cardiovascular diseases, accounting for one in every three deaths. Annually, about one in every six U.S. healthcare dollars is spent on cardiovascular disease. […]

Read More »

Mylan Raises Offer to Acquire Perrigo

POTTERS BAR, England, April 29, 2015 /PRNewswire/ — Mylan N.V. (NASDAQ: MYL) today announced that, further to its announcement issued pursuant to Rule 2.5 of the Irish Takeover Rules on April 24, 2015 (the “Rule 2.5 Announcement“), it has increased its offer to acquire the issued and to be issued shares of Perrigo (NYSE: PRGO; TASE).  Under the terms of […]

Read More »

Pfizer cuts full-year forecast on stronger dollar

(Reuters) – U.S. drugmaker Pfizer Inc (PFE.N) cut its full-year revenue and profit forecast, blaming a stronger dollar. However, the drugmaker reported a better-than-expected first-quarter profit, helped by demand for its vaccines and cancer drugs. Pfizer’s shares were roughly unchanged at $34.62 in premarket trade on Tuesday morning. The company, which got 60 percent of […]

Read More »

Strong Merck cancer drug sales upstage rival Bristol-Myers

(Reuters) – Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales. Bristol shares fell as much as 2.7 percent and closed off 1 percent after reporting sales […]

Read More »

Merck shares jump on strong earnings, Januvia safety data

(Reuters) – Merck & Co’s (MRK.N) shares jumped almost 5 percent after the U.S. drugmaker reported better-than-expected quarterly results and released favorable data late Monday about the safety of its Januvia diabetes drug. The second-largest U.S. drugmaker on Tuesday said it earned $953 million, or 33 cents per share, in the first quarter. That compared […]

Read More »

Bristol-Myers tops forecasts, helped by Abilify royalty adjustment

(Reuters) – Bristol-Myers Squibb Co (BMY.N) reported better-than- expected quarterly results, helped by cost cuts and a higher estimate of royalties owed the company from sales of its Abilify schizophrenia treatment. The U.S. drugmaker, whose shares rose 2 percent in premarket trading, on Tuesday said it earned $1.19 billion, or 71 cents per share, in […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom